{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:28:50Z","timestamp":1767832130155,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[1996,3,1]],"date-time":"1996-03-01T00:00:00Z","timestamp":825638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1996,3]]},"DOI":"10.1007\/bf02245619","type":"journal-article","created":{"date-parts":[[2005,11,14]],"date-time":"2005-11-14T23:38:09Z","timestamp":1132011489000},"page":"176-187","source":"Crossref","is-referenced-by-count":48,"title":["Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine"],"prefix":"10.1007","volume":"124","author":[{"given":"H. Y.","family":"Meltzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. A.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. A.","family":"Cola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02245619_CR1","first-page":"346","volume":"52","author":"LD Alphs","year":"1991","unstructured":"Alphs LD, Lee HS (1991) Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 52:346\u2013348","journal-title":"J Clin Psychiatry"},{"key":"BF02245619_CR2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/00004714-199412000-00009","volume":"14","author":"NM Bacher","year":"1994","unstructured":"Bacher NM, Sanzone MM, Kamp B (1994) Cyproheptadine in treatment-resistant chronic schizophrenics with prior negative response to fluoxetine. J Clin Psychopharmacol 14:424\u2013425","journal-title":"J Clin Psychopharmacol"},{"key":"BF02245619_CR3","first-page":"260","volume":"24","author":"RL Borison","year":"1988","unstructured":"Borison RL, Diamond BI, Sinha D, Gupta RP, Ajboye PA (1988) Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 24:260\u2013263","journal-title":"Psychopharmacol Bull"},{"key":"BF02245619_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/ajp.151.1.20","volume":"151","author":"A Breier","year":"1994","unstructured":"Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:20\u201326","journal-title":"Am J Psychiatry"},{"key":"BF02245619_CR5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/BF02244818","volume":"106","author":"PR Buckland","year":"1992","unstructured":"Buckland PR, O'Donovan MC, McGriffin P (1992) Changes in dopamine D1, D2, and D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology 106:479\u2013483","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0028-3908(93)90146-T","volume":"32","author":"PR Buckland","year":"1993","unstructured":"Buckland PR, O'Donovan MC, McGriffin P (1993) Clozapine and sulpiride up-regulate dopamine D3 receptormRNA levels. Neuropharmacology 32:901\u2013907","journal-title":"Neuropharmacology"},{"key":"BF02245619_CR7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","volume":"13","author":"G Chouinard","year":"1993","unstructured":"Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25\u201340","journal-title":"J Clin Psychopharmacol"},{"key":"BF02245619_CR8","first-page":"699","volume":"14","author":"KL Davis","year":"1979","unstructured":"Davis KL, Rosenberg GS (1979) Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry 14:699\u2013703","journal-title":"Biol Psychiatry"},{"key":"BF02245619_CR9","first-page":"900","volume":"26","author":"BI Diamond","year":"1986","unstructured":"Diamond BI, Borison RL (1986) Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Psychopharmacol Bull 26:900\u2013905","journal-title":"Psychopharmacol Bull"},{"key":"BF02245619_CR10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/070674379403900318","volume":"39","author":"R Dickson","year":"1994","unstructured":"Dickson R, Williams R, Dalby JT (1994) Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation. Can J Psychiatry 39:184","journal-title":"Can J Psychiatry"},{"key":"BF02245619_CR11","first-page":"945","volume":"16","author":"B Ekblom","year":"1974","unstructured":"Ekblom B, Haggstrom JE (1974) Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 16:945\u2013957","journal-title":"Curr Ther Res"},{"key":"BF02245619_CR12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00464798","volume":"83","author":"B Ekblom","year":"1984","unstructured":"Ekblom B, Eriksson K, Lindstr\u00f6m LH (1984) Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology 83:293\u2013294","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00690943","volume":"91","author":"K Eklund","year":"1987","unstructured":"Eklund K (1987) Supersensitivity and clozapine withdrawal. Psychopharmacology 91:135","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archpsyc.1978.01770310043002","volume":"35","author":"J Endicott","year":"1978","unstructured":"Endicott J, Spitzer RL (1978) A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 35:837\u2013844","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245619_CR15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0091-3057(79)90028-5","volume":"11","author":"H Fink","year":"1979","unstructured":"Fink H, Morgenstern R, Oelssner W (1979) Psychotomimetics potentiate locomotor hyperactivity induced by dopaminergic drugs. Pharmacol Biochem Behav 11:479\u2013482","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02245619_CR16","first-page":"1706","volume":"24","author":"KA Fischer-Cornelssen","year":"1974","unstructured":"Fischer-Cornelssen KA, Ferner UJ, Steiner H (1974) Multifokale Psychopharmaka-prufung (\u201cMultihospital Trial\u201d). Arzneimittelforschung 24:1706\u20131724","journal-title":"Arzneimittelforschung"},{"key":"BF02245619_CR17","first-page":"238","volume":"40","author":"JC Garrison","year":"1990","unstructured":"Garrison JC (1990) Histamine, bradykinesia, 5-hydroxytryptamine, and their antagonists. In Gelenberg AJ, Doller JC (1979) Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psychiatry 40:238\u2013240","journal-title":"J Clin Psychiatry"},{"key":"BF02245619_CR18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1600-0447.1974.tb09706.x","volume":"50","author":"J Gerlach","year":"1974","unstructured":"Gerlach J, Koppelhus P, Helweg E, Manrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial. Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410\u2013424","journal-title":"Acta Psychiatr Scand"},{"key":"BF02245619_CR19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpsyc.1995.03950150005001","volume":"52","author":"PL Gilbert","year":"1995","unstructured":"Gilbert PL, Harris WJ, McAdams LA, Jeste DA (1995) Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 52:173\u2013188","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245619_CR20","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/0006-3223(92)90124-I","volume":"31","author":"D Glovinsky","year":"1992","unstructured":"Glovinsky D, Kirch DG, Wyatt RJ (1992) Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry 31:968\u2013970","journal-title":"Biol Psychiatry"},{"key":"BF02245619_CR21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/BF00451692","volume":"98","author":"R Halperin","year":"1989","unstructured":"Halperin R, Guerin JJ Jr, Davis KL (1989) Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. Psychopharmacology 98:386\u2013391","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR22","first-page":"383","volume":"13","author":"M Hasegawa","year":"1993","unstructured":"Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY (1993) Relationship between clinical efficacy and clozapine plasma concentrations in schizophrenia: effect of smoking. J ClinPsychopharmacol 13:383\u2013390","journal-title":"J ClinPsychopharmacol"},{"issue":"3","key":"BF02245619_CR23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","volume":"10","author":"DW Heinrichs","year":"1984","unstructured":"Heinrichs DW, Hanlon TE, Carpenter WT (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10[3]:388\u2013398","journal-title":"Schizophr Bull"},{"key":"BF02245619_CR24","first-page":"494","volume":"37","author":"G Hogarty","year":"1976","unstructured":"Hogarty G, Ulrich R, Mussare F, Aristigueta N (1976) Drug discrimination among long-term successfully maintained schizophrenic outpatients. Dis Nerv Syst 37:494\u2013500","journal-title":"Dis Nerv Syst"},{"key":"BF02245619_CR25","first-page":"348","volume":"256","author":"J Ichikawa","year":"1991","unstructured":"Ichikawa J, Meltzer HY (1991) Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J Pharmacol Exp Ther 256:348\u2013357","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02245619_CR26","doi-asserted-by":"crossref","unstructured":"Ichikawa J, Meltzer HY (1995) DOI, a 5-HT2C\/2A receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res (in press)","DOI":"10.1016\/0006-8993(95)00865-N"},{"key":"BF02245619_CR27","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/j.1471-4159.1992.tb10975.x","volume":"58","author":"J Ichikawa","year":"1992","unstructured":"Ichikawa J, Meltzer HY (1992) Amperozide, a novel antipsychotic drug, inhibits the ability ofd-amphetamine to increase dopamine release in vitro in rat striatum and nucleus accumbens. J Neurochem 58:2285\u20132291","journal-title":"J Neurochem"},{"key":"BF02245619_CR28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/BF00207228","volume":"93","author":"C Idzikowski","year":"1987","unstructured":"Idzikowski C, Cowen PJ, Mutt D, Mills FJ (1987) The effects of chronic ritanserin treatment on sleep and the neuroendocrine response toL-tryptophan. Psychopharmacology 93:416\u2013420","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2125.1991.tb05514.x","volume":"31","author":"C Idzikowski","year":"1991","unstructured":"Idzikowski C, Mills FJ, James RJ (1991) A dose-response study examining the effects of ritanserin on human slow wave sleep. Br J Clin Pharmacol 31:193\u2013196","journal-title":"Br J Clin Pharmacol"},{"key":"BF02245619_CR30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl","key":"BF02245619_CR31","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1007\/BF00442575","volume":"99","author":"P Krupp","year":"1989","unstructured":"Krupp P, Barnes P (1989) Leponex\u00ae-associated granulocytopenia: a review of the situation. Psychopharmacology (Suppl) 99:S118-S121","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR32","first-page":"1262","volume":"264","author":"M Kuoppam\u00e4ki","year":"1993","unstructured":"Kuoppam\u00e4ki M, Sepp\u00e4l\u00e4 T, Syv\u00e4lahti E, Hietala J (1993) Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 264:1262\u20131267","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl B","key":"BF02245619_CR33","first-page":"82","volume":"55","author":"MA Lee","year":"1994","unstructured":"Lee MA, Thompson P, Meltzer HY (1994) Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55[Suppl B]:82\u201387","journal-title":"J Clin Psychiatry"},{"key":"BF02245619_CR34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00004850-199506000-00002","volume":"10","author":"HS Lee","year":"1995","unstructured":"Lee HS, Song DH, Kim JH, Lee YM, Han ES, Yoo KJ (1995) Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int Clin Psychopharmacol 10:67\u201372","journal-title":"Int Clin Psychopharmacol"},{"key":"BF02245619_CR35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0165-1781(94)90021-3","volume":"54","author":"DH Linszen","year":"1994","unstructured":"Linszen DH, Dinegemans PM, Lenoir ME, Nugter MA, Scholte WF, Van der Does AJW (1994) Relapse criteria in schizophrenic disorders: difference perspectives. Psychiatry Res 54:273\u2013281","journal-title":"Psychiatry Res"},{"key":"BF02245619_CR36","first-page":"565","volume":"19","author":"DM Llorca","year":"1993","unstructured":"Llorca DM, Wolf MA, Laneon C, Bougerol T (1993) Efficcat\u00e9 compare\u00e9 de la bromocriptine, de la carbamaz\u00e9pine et de la cyproheptadine, schizophr\u00e8nes chroniques r\u00e9sistants. Encephale 19:565\u2013571","journal-title":"Encephale"},{"key":"BF02245619_CR37","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1176\/ajp.137.11.1395","volume":"137","author":"DJ Luchins","year":"1980","unstructured":"Luchins DJ, Freed WJ, Wyatt RJ (1980) The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 137:1395\u20131398","journal-title":"Am J Psychiatry"},{"key":"BF02245619_CR38","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/0024-3205(89)90027-1","volume":"45","author":"S Matsubara","year":"1989","unstructured":"Matsubara S, Meltzer HY (1989) Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci 45:1397\u20131406","journal-title":"Life Sci"},{"key":"BF02245619_CR39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/schbul\/17.2.263","volume":"17","author":"HY Meltzer","year":"1991","unstructured":"Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263\u2013287","journal-title":"Schizophr Bull"},{"issue":"Suppl 17","key":"BF02245619_CR40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/S000712500029692X","volume":"160","author":"HY Meltzer","year":"1992","unstructured":"Meltzer HY (1992a) Dimensions of outcome with clozapine. Br J Psychiatry 160 [Suppl 17]:46\u201353","journal-title":"Br J Psychiatry"},{"key":"BF02245619_CR41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","volume":"18","author":"HY Meltzer","year":"1992","unstructured":"Meltzer HY (1992b) Treatment of the neuroleptic non-responsive schizophrenic patients. Schizophr Bull 18:515\u2013542","journal-title":"Schizophr Bull"},{"key":"BF02245619_CR42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/npp.1994.31","volume":"11","author":"DD Miller","year":"1994","unstructured":"Miller DD, Flaum M, Arndt S, Fleming F, Andreasan NC (1994) Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 11:11\u201320","journal-title":"Neuropsychopharmacology"},{"key":"BF02245619_CR43","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/248596a0","volume":"248","author":"RJ Miller","year":"1974","unstructured":"Miller RJ, Hiley CR (1974) Antimuscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 248:596\u2013597","journal-title":"Nature"},{"key":"BF02245619_CR44","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1471-4159.1990.tb02358.x","volume":"54","author":"JF Nash","year":"1990","unstructured":"Nash JF, Meltzer HY, Gudelsky GA (1990) Effect of 3,4-methylenedioxymethamphetamine on 3,4-di-hydroxyphenylalanine in the striatum and nucleus accumulation in the striatum and nucleus accumbens. J Neurochem 54:1062\u20131067","journal-title":"J Neurochem"},{"key":"BF02245619_CR45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archpsyc.1992.01820080051008","volume":"49","author":"TC Neylan","year":"1992","unstructured":"Neylan TC, Van Kammen DP, Kelley ME, Peters JL (1992) Sleep in schizophrenic patients on and off haloperidol therapy: clinically stable versus relapsed patients. Arch Gen Psychiatry 49:643\u2013649","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245619_CR46","first-page":"149","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham D (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:149\u2013165","journal-title":"Psychol Rep"},{"key":"BF02245619_CR47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00004714-199304000-00012","volume":"13","author":"MA Parsa","year":"1993","unstructured":"Parsa MA, Al-Lanhram Y, Ramirez LF, Meltzer HY (1993) Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 13:154\u2013155","journal-title":"J Clin Psychopharmacol"},{"key":"BF02245619_CR48","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/BF00431719","volume":"86","author":"A Per\u00e9nyi","year":"1985","unstructured":"Per\u00e9nyi A, Kunsz E, Bagdy G (1985) Early relapse after sudden withdrawal or dose reduction of clozapine. Psychopharmacology 86:244","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1176\/ajp.148.10.1406-b","volume":"148","author":"PJ Perry","year":"1991","unstructured":"Perry PJ, Miller DD, Arndt S, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231\u2013235","journal-title":"Am J Psychiatry"},{"key":"BF02245619_CR50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1192\/bjp.115.523.679","volume":"115","author":"RF Prien","year":"1968","unstructured":"Prien RF, Cole J, Belkin N (1968) Relapse in chronic schizophrenics following abrupt withdrawal of tranquilizing medication. Br J Psychiatry 115:679\u2013686","journal-title":"Br J Psychiatry"},{"key":"BF02245619_CR51","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/BF00431458","volume":"84","author":"NMJ Rupniak","year":"1984","unstructured":"Rupniak NMJ, Kilpatrick G, Hall MD, Jenner P, Marsden CD (1984) Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology 84:512\u2013519","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/BF02244614","volume":"100","author":"C Schremmer","year":"1990","unstructured":"Schremmer C, Morgenstern R, Fink H, Oh T (1990) Atypical neurlopetics suppress dopaminergic behavioral supersensitivity. Psychopharmacology 100:399\u2013403","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR53","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/BF02244239","volume":"101","author":"AL Sharpley","year":"1990","unstructured":"Sharpley AL, Solomon RA, Fernando AI, da Roza Davis JM, Cown PJ (1990) Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology 101:568\u2013569","journal-title":"Psychopharmacology"},{"key":"BF02245619_CR54","doi-asserted-by":"crossref","unstructured":"Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Sramek JJ, Kurtz NM, Cutler NR (1995) Cholinergic rebound and rapid onset psychosis following abrupt clozapine with-drawal. Schizophr Bull (in press)","DOI":"10.1093\/schbul\/22.4.591"},{"key":"BF02245619_CR55","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archpsyc.1979.01780060047005","volume":"36","author":"B Shopsin","year":"1979","unstructured":"Shopsin B, Klein H, Aaronson M, Collora M (1979) Clozapine, chlorpromazine and placebo in newly hospitalized, acutely schizophrenic patients. Arch Gen Psychiatry 36:657\u2013664","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245619_CR56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/schbul\/21.2.333","volume":"21","author":"D Shore","year":"1995","unstructured":"Shore D, Matthew S, Cott J, Lieberman JA (1995) Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 21:333\u2013338","journal-title":"Schizophr Bull"},{"key":"BF02245619_CR57","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0006-3223(89)90206-0","volume":"25","author":"H Silver","year":"1989","unstructured":"Silver H, Blacker M, Weller MP, Lerer B (1989) Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 25:502\u2013504","journal-title":"Biol Psychiatry"},{"key":"BF02245619_CR58","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0006-3223(91)90317-F","volume":"30","author":"H Silver","year":"1991","unstructured":"Silver H, Blacker M, Weller MP, Lerer B (1991) Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo controlled study. Biol Psychiatry 30:523\u2013525","journal-title":"Biol Psychiatry"},{"key":"BF02245619_CR59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/026988118900300301","volume":"3","author":"RA Solomon","year":"1984","unstructured":"Solomon RA, Sharpley AL, Cowen PJ (1984) Increased slow wave sleep with 5-HT2 receptor antagonists; detection by ambulatory EEG recording and automatic sleep stage analysis. J Psychopharmacol 3:125\u2013129","journal-title":"J Psychopharmacol"},{"key":"BF02245619_CR60","first-page":"684","volume":"266","author":"SM Sorensen","year":"1993","unstructured":"Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Kettler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993) Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684\u2013691","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02245619_CR61","first-page":"1789","volume":"52","author":"LM Specchio","year":"1976","unstructured":"Specchio LM, Puca FM, Genco S, Candeliere G, Galeone D, Dammacco F (1976) Effectti della ciproheptadine sul sonno dellumo normale. Boll Soc Ital Biol Sper 52:1789\u20131793","journal-title":"Boll Soc Ital Biol Sper"},{"key":"BF02245619_CR62","unstructured":"Stutzmann JM, Eon B, Roux M, Lucas M, Blanchard JC, Laduron RM (1990) RP 62203, a 5-HT2 antagonist, enhances slow wave sleep in rats. 17th Congress of Collegium Internationale Neuropharmacologicum, Kyoto, Japan, Abstract 1394"},{"key":"BF02245619_CR63","first-page":"256","volume":"198","author":"H Rizen Van","year":"1972","unstructured":"Van Rizen H (1972) Different central effects of the 5-HT antagonists mianserin and cyproheptadine. Arch Int Pharmacodyn 198:256\u2013269","journal-title":"Arch Int Pharmacodyn"},{"key":"BF02245619_CR64","first-page":"21","volume":"71","author":"E Vencovsky","year":"1975","unstructured":"Vencovsky E, Peterova E, Baudis P (1975) Comparison of therapeutic effect of clozapine and chlorpromazine. Ceskoslovenska Psychiatric 71:21\u201326","journal-title":"Ceskoslovenska Psychiatric"},{"key":"BF02245619_CR65","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0006-8993(89)90833-0","volume":"487","author":"CA Wilmot","year":"1989","unstructured":"Wilmot CA, Szczepanick AM (1989) Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT) and dopamine (D2) receptors in the rat brain. Brain Res 487:288\u2013298","journal-title":"Brain Res"},{"issue":"Suppl B","key":"BF02245619_CR66","first-page":"8","volume":"55","author":"BK Yamamoto","year":"1994","unstructured":"Yamamoto BK, Pehek EA, Meltzer HY (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55 [Suppl B]:8\u201314","journal-title":"J Clin Psychiatry"},{"issue":"A","key":"BF02245619_CR67","first-page":"19","volume":"21","author":"M Zaplet\u00e1lek","year":"1980","unstructured":"Zaplet\u00e1lek M, Preiningerova O, Hanus H (1980) Does clozapine cause dependence? (German) Agressologie 21[A]:19\u201322","journal-title":"(German) Agressologie"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02245619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02245619\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02245619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T22:00:00Z","timestamp":1586556000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02245619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,3]]},"references-count":67,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[1996,3]]}},"alternative-id":["BF02245619"],"URL":"https:\/\/doi.org\/10.1007\/bf02245619","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,3]]}}}